



CELEBRATING A DECADE OF PUBLISHING AND MEDICAL ADVANCEMENT

2013

First issue published May 29, 2013, with five papers, including:

- Introducing the Society for Immunotherapy of Cancer's new journal: Journal for ImmunoTherapy of Cancer
 [Editorial]
- Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation [Review]

2016

Guidelines and Consensus Statements section added, leading to the publication of 30+ papers, including:



The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

■ Top-read SITC Clinical Practice Guideline

Paper with all-time greatest Altmetric score published:



Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy



2017

JITC's most-read and cited paper of all time published:

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

2018

JITC moves to continuous publication model to support the timely release of research

Notable series published in 2018:

- Microbial-Based Cancer Immunotherapy
- Emerging Immunotherapeutic Agents

2021

First video abstract published:

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Notable series published:

COVID-19 and Cancer Immunotherapy

2020

Two new sections launched on emerging areas of the field:

- Immune Cell Therapies and Immune Cell Engineering
- Oncolytic and Local Immunotherapy

Notable series published:

Immune Checkpoints Beyond PD-1



QJITCancer Twitter account extends reach of *JITC* articles. Highest engagement received by: *Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies*

2022

- Published 10th Anniversary Editorial
- JITC achieves more than 40,000 total citations



Visit the *JITC* **Anniversary page** to learn more about the 10-year journey and major milestones.

